COVID-19 update: Remdesivir readout in weeks; hospital-use diagnostic under development; antibodies advancing
Initial signals from two ongoing trials in China of Gilead’s remdesivir to treat COVID-19 should be available in a few weeks, Marie-Paule Kieny said at a WHO press conference Wednesday. Assistant Director-General Kieny co-chaired the Feb. 11-12 Global Research and Innovation Forum dedicated to mobilizing responses to the COVID-19 outbreak.
The pair of placebo-controlled trials, which are being coordinated by the China-Japan Friendship Hospital in Beijing, are evaluating remdesivir to treat COVID-19 (2019-nCoV) infection. According to ClinicalTrials.gov, a trial to treat mild to moderate infection, which is not yet recruiting, will enroll 308 patients; a trial to treat severe infection has begun recruitment and plans to enroll 452 patients...